Back to top

Image: Bigstock

AT&T Invests in Kentucky to Improve 4G LTE Network Setup

Read MoreHide Full Article

AT&T Inc. (T - Free Report) communicated that it has invested more than $800 million in its Kentucky wireless and wired networks over the last three years to reinforce its market dominance. With these planned investments, the telecom giant aims to enhance reliability, coverage, speed and overall performance for consumers and business houses.

In order to develop 4G LTE network, the telecom juggernaut has established approximately 200 cell sites, which includes 110 small cells and 89 macro cell towers. Kentucky is broadly covered by both 3G and 4G LTE technology, which provides last-mile seamless network connection to more than 400 million people in North America. According to a global leader in Internet testing and analysis, Ookla, AT&T’s 4G LTE network provides Internet connection with download speeds of up to 25 Mbps, thereby boosting wider coverage with an agile network infrastructure in more than 57 Kentucky districts.

With this expansion endeavor, the wireless carrier has improved critical services that support public safety and first responders using the FirstNet communications platform. Markedly, this platform involves a public-private partnership with the First Responder Network Authority — an independent agency within the federal government. AT&T has also helped meet customers’ needs mostly in rural areas by participating in the FCC’s Connect America Fund. By the end of 2020, AT&T is expected to deploy, maintain and offer voice services and Internet access to more than 1.1 million rural homes and small business locations in FCC-identified areas.

Over the past five years, AT&T has invested around $145 billion in wireless and wireline networks, including capital investments and acquisitions of wireless spectrum and operations. Its fiber network is one of the nation’s largest and connects more IoT devices compared to any other provider in North America.

For the three-year period of 2020-2022, AT&T expects consolidated revenue growth of 1-2% per year. Adjusted earnings are expected between $4.50 and $4.80 per share by 2022, with adjusted EBITDA margin of 35%. Free cash flow is anticipated between $30 billion and $32 billion in 2022, with net debt-to-adjusted EBITDA of 2x to 2.3x as 100% debt related to the acquisition of Time Warner assets is likely to be repaid.

Moving forward, AT&T anticipates gaining an advantage over rivals through edge computing services that allow businesses to route application-specific traffic to where they need it and where it’s most effective — in the cloud, the network or on their premises. The company is focused on building networks that will enable fiber-based connectivity and LTE to work efficiently side by side with 5G solutions, making the most of business transformation. AT&T’s wireless network covers more than 99% of Americans and is reportedly the fastest in the nation. Sustainable subscriber growth, backed by network expansion, remains a key driver.

Driven by solid execution of operational strategies, the stock has gained 24.5% compared with the industry’s growth of 10.5% in the past year. The company topped earnings estimates thrice in the trailing four quarters, delivering a beat of 0.9%, on average.



Zacks Rank & Stocks to Consider

AT&T currently has a Zacks Rank #3 (Hold).

Some better-ranked stocks in the broader industry are America Movil, S.A.B. de C.V. (AMX - Free Report) , Sogou Inc. (SOGO - Free Report) and The Rubicon Project, Inc. (RUBI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

America Movil has a long-term earnings growth rate of 17.2%.

Sogou has a long-term earnings growth rate of 20.2%.

Rubicon surpassed earnings estimates in each of the trailing four quarters, the surprise being 86.7%, on average.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Published in